Patients with STK11/KEAP1-mutant lung adenocarcinoma may experience limited benefit from checkpoint blockade therapies highlighting unmet need for improved treatment strategies [74, 75]. The gene discussed is KEAP1; the disease is lung adenocarcinoma.